Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study

Basit Öğe Kaydı
dc.contributor.authorBilici, Ahmet
dc.contributor.authorKoca, Sinan
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorAydin, Sabin Goktas
dc.contributor.authorEraslan, Emrah
dc.contributor.authorKaplan, Muhammed Ali
dc.contributor.authorOcak, Birol
dc.date.accessioned2024-02-23T13:43:51Z
dc.date.available2024-02-23T13:43:51Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractAimDescription of patient characteristics, effectiveness and safety in Turkish patients treated with pazopanib for metastatic soft tissue sarcoma (STS).Patients and methodsThis multicenter study is based on retrospective review of hospital medical records of patients (>= 18 years) treated with pazopanib for non-adipocytic metastatic STS at 37 Oncology clinics across Turkey. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) were evaluated with further analysis of data on the three most common histological subtypes (leiomyosarcoma [LMS], undifferentiated pleomorphic sarcoma [UPS], synovial sarcoma [SS]) in the cohort.ResultsData of 552 adults (57.6% women, median age: 52 years) were analyzed. DCR and ORR were 43.1% and 30.8%, respectively. Median PFS was 6.7 months and OS was 13.8 months. For LMS, UPS and SS, median PFSs were 6.1, 5.9 and 7.53 months and median OSs were 15.03, 12.87 and 12.27 months, respectively. ECOG >= 2 was associated with poor PFS and OS. Liver metastasis was only a factor for progression. Second-line use of pazopanib (vs. front-line) was associated with better PFS, its use beyond third line predicted worse OS. Adverse events (AE) occurred in 82.7% of patients. Most common AEs were fatigue (58.3%) and anorexia (52.3%) which were graded as >= 3 in 8.2% and 7.4% of patients, respectively.ConclusionPazopanib is effective and well-tolerated in treatment of non-adipocytic metastatic STS. Its earlier use (at second-line), good performance status may result in better outcomes. Worldwide scientific collaborations are important to gain knowledge on rarer STS subtypes by conducting studies in larger patient populations.en_US
dc.identifier.doi10.1007/s00432-023-04766-3
dc.identifier.endpage8253en_US
dc.identifier.issn0171-5216
dc.identifier.issn1432-1335
dc.identifier.issue11en_US
dc.identifier.pmid37067546en_US
dc.identifier.scopus2-s2.0-85152801829en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage8243en_US
dc.identifier.urihttps://doi.org/10.1007/s00432-023-04766-3
dc.identifier.urihttps://hdl.handle.net/20.500.12452/10951
dc.identifier.volume149en_US
dc.identifier.wosWOS:000972021200003en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal Of Cancer Research And Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPazopaniben_US
dc.subjectSoft Tissue Sarcomaen_US
dc.subjectTargeted Therapyen_US
dc.subjectSynovial Sarcomaen_US
dc.subjectLeiomyosarcomaen_US
dc.subjectMetastatic Soft Tissue Sarcomaen_US
dc.titleReal-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu